Supplementary Data from 5-Fluorouracil Enhances the Antitumor Activity of the Glutaminase Inhibitor CB-839 against <i>PIK3CA</i>-Mutant Colorectal Cancers

Supplementary Figures 1-6 and Tables 1-3. Figure S1. PIK3CA mutant cells are more sensitive to a glutaminase inhibitor CB-839 than their WT counterparts. Figure S2. CB-839 enhances 5-FU tumor inhibitory effect in PIK3CA mutant CRC. Figure S3. Genes and pathways that are up-regulated in PIK3CA mutant cells after glutamine deprivation. Figure S4. Characterization of Nrf2 and its targets in CRC cells. Figure S5. CB-839 and 5-FU combinational treatment induces more DNA damage. Figure S6. Phase I clinical trial. Table S1: Patient Baseline Characteristics. Table S2. Patient information. Table S3. Treatment Related Adverse Events (all grade 3/4 AEs and grade 1/2 AEs seen in {greater than or equal to} 10% of patients).